Peer-reviewed veterinary case report
High BCL2 and MYC in dog lymphoma don't predict chemo outcome
By Curran, K M et al.·Published in Veterinary and comparative oncology·2017·College of Veterinary Medicine and Biomedical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: BCL2 and MYC are expressed at high levels in canine diffuse large B-cell lymphoma but are not predictive for outcome in dogs treated with CHOP chemotherapy.
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with diffuse large B-cell lymphoma (DLBCL), the most common blood cancer in dogs, were treated with a chemotherapy regimen called CHOP. Researchers looked at the levels of two proteins, MYC and BCL2, to see if they could predict how well the dogs would respond to treatment. While the dogs showed high levels of these proteins, their presence did not help predict the outcome of the treatment. However, completing the CHOP chemotherapy was linked to better results, meaning that sticking to the treatment plan was crucial for improving the dogs' chances of recovery.
People also search for: dog lymphoma treatment · canine DLBCL prognosis · CHOP chemotherapy for dogs
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common haematopoietic malignancy in dogs. Recently, MYC and BCL2 expression levels determined with immunohistochemistry (IHC) were found to be prognostic in people with DLBCL. We hypothesized that canine DLBCL can be similarly subdivided into prognostic subtypes based on expression of MYC and BCL2. Cases of canine DLBCL treated with CHOP chemotherapy were retrospectively collected and 43 dogs had available histologic tissue and complete clinical follow-up. Median values of percent immunoreactive versus immunonegative cells were used to determine positive or negative expression status. Completion of CHOP was significantly associated with a positive outcome. Compared with human patients, our canine DLBCL patients had high IHC expression of both MYC and BCL2, and relative expression levels of one or both markers were not associated with clinical outcome.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27514648/